We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
- Recent BIIB Stock Price: $276.61
- Yearly Gain for BIIB stock: -30.53%
- Market Cap for BIIB stock: $28.70B
- P/E Ratio for BIIB stock: 14.121
Will BIIB's stock price go up? Is there an accurate BIIB stock forecast available?
TipRanks.com reports that Biogen currently has 24 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $258.35. The target pricing ranges from a high BIIB forecast of $360.00 down to a low forecast of $190.00. Biogen (BIIB)’s last closing stock price was $276.61 which would put the average price target at -6.60% upside.
In addition, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BIIB stock.
Other analysts covering BIIB include:
- Steve Chesney of Atlantic Equities issued a Hold rating with the price target of $ 200 on 23 hours ago
- Brian Skorney of Robert W. Baird issued a Buy rating with the price target of $ 340 on 23 hours ago
- Yatin Suneja of Guggenheim issued a Hold rating with the price target of $ 190 on 23 hours ago
If you are wondering if BIIB is a good stock to buy, here are 3rd party ratings for BIIB stock:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 31% (77 out of 251)
What is the sentiment on the street regarding Biogen? (Current ratings compiled by TipRanks.com)
- News Sentiment for BIIB stock: Bullish
- Blogger Consensus for BIIB stock: Bullish
- Media Buzz for BIIB stock: Very High
- Insider Signal for BIIB stock: n/a
- Investor Sentiment for BIIB stock: Negative
- Hedge Fund signal for BIIB stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on BIIB stock including scouring the social networks like BIIB StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BIIB stock chart >>
Summary: Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A'.'Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
- Recent PRTA Stock Price: $58
- Yearly Gain for PRTA stock: -56.32%
- Market Cap for PRTA stock: $1.45B
- P/E Ratio for PRTA stock: 1232.27
Will PRTA's stock price go up? Is there an accurate PRTA stock forecast available?
TipRanks.com reports that Prothena currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $68.83. The target pricing ranges from a high PRTA forecast of $81.00 down to a low forecast of $52.00. Prothena (PRTA)’s last closing stock price was $58 which would put the average price target at 18.67% upside.
In addition, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on PRTA stock.
Other analysts covering PRTA include:
- Tazeen Ahmad of Bank of America Securities issued a Buy rating with the price target of $ 65 on 23 hours ago
- Jason Butler of JMP Securities issued a Buy rating with the price target of $ 81 on 23 hours ago
- Michael Yee of Jefferies issued a Buy rating with the price target of $ 75 on 1 day ago
- Neena Bitritto-Garg of Citigroup issued a Buy rating with the price target of $ 65 on 1 month ago
If you are wondering if PRTA is a good stock to buy, here are 3rd party ratings for PRTA stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 31% (77 out of 251)
What is the sentiment on the street regarding Prothena? (Current ratings compiled by TipRanks.com)
- News Sentiment for PRTA stock: Very Bullish
- Blogger Consensus for PRTA stock: Bullish
- Media Buzz for PRTA stock: Very High
- Insider Signal for PRTA stock: Positive
- Investor Sentiment for PRTA stock: Very Negative
- Hedge Fund signal for PRTA stock: Negative
The stock market is extremely volatile, and you need to do your own research on PRTA stock including scouring the social networks like PRTA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for PRTA stock chart >>
Summary: Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Illumina generates revenue from two segments - Product and Service. Product are primarily attributed to the partnerships and collaborations to develop distributable clinical in-vitro diagnostics for Illumina sequencers. Service include genotyping and sequencing services as well as instrument maintenance contracts.
- Recent ILMN Stock Price: $201.29
- Yearly Gain for ILMN stock: -54.45%
- Market Cap for ILMN stock: $29.39B
- P/E Ratio for ILMN stock: -2292.515
Will ILMN's stock price go up? Is there an accurate ILMN stock forecast available?
TipRanks.com reports that Illumina currently has 15 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $250.36. The target pricing ranges from a high ILMN forecast of $380.00 down to a low forecast of $130.00. Illumina (ILMN)’s last closing stock price was $201.29 which would put the average price target at 24.38% upside.
In addition, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ILMN stock.
Other analysts covering ILMN include:
- Puneet Souda of SVB Securities issued a Hold rating with the price target of $ 220 on 2 days ago
- Kyle Mikson CFA of Canaccord Genuity issued a Buy rating with the price target of $ 380 on 2 days ago
- Unknown Analyst of CFRA issued a Sell rating with the price target of $ 175 on 3 weeks ago
- David Westenberg of Piper Sandler issued a Buy rating with the price target of $ 320 on 3 weeks ago
If you are wondering if ILMN is a good stock to buy, here are 3rd party ratings for ILMN stock:
- TipRanks.com: Hold
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Strong Sell, Top 31% (77 out of 251)
What is the sentiment on the street regarding Illumina? (Current ratings compiled by TipRanks.com)
- News Sentiment for ILMN stock: Neutral
- Blogger Consensus for ILMN stock: Neutral
- Media Buzz for ILMN stock: Very Low
- Insider Signal for ILMN stock: n/a
- Investor Sentiment for ILMN stock: Neutral
- Hedge Fund signal for ILMN stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on ILMN stock including scouring the social networks like ILMN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ILMN stock chart >>
Summary: Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts.
- Recent OCUL Stock Price: $4.13
- Yearly Gain for OCUL stock: -58.91%
- Market Cap for OCUL stock: $331.73M
- P/E Ratio for OCUL stock: -4.631
Will OCUL's stock price go up? Is there an accurate OCUL stock forecast available?
TipRanks.com reports that Ocular Therapeutix currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $15.00. The target pricing ranges from a high OCUL forecast of $25.00 down to a low forecast of $10.00. Ocular Therapeutix (OCUL)’s last closing stock price was $4.13 which would put the average price target at 263.20% upside.
In addition, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on OCUL stock.
Other analysts covering OCUL include:
- Joseph Catanzaro of Piper Sandler issued a Buy rating with the price target of $ 10 on 1 day ago
- Jonathan Wolleben of JMP Securities issued a Buy rating with the price target of $ 25 on 1 day ago
- Caroline Palomeque of Berenberg Bank issued a Buy rating with the price target of $ 15 on 1 month ago
If you are wondering if OCUL is a good stock to buy, here are 3rd party ratings for OCUL stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 31% (77 out of 251)
What is the sentiment on the street regarding Ocular Therapeutix? (Current ratings compiled by TipRanks.com)
- News Sentiment for OCUL stock: Very Bullish
- Blogger Consensus for OCUL stock: Bullish
- Media Buzz for OCUL stock: Very High
- Insider Signal for OCUL stock: n/a
- Investor Sentiment for OCUL stock: Negative
- Hedge Fund signal for OCUL stock: Neutral
The stock market is extremely volatile, and you need to do your own research on OCUL stock including scouring the social networks like OCUL StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for OCUL stock chart >>
Summary: PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States.
- Recent PHAS Stock Price: $0.257
- Yearly Gain for PHAS stock: -75.32%
- Market Cap for PHAS stock: $37.89M
- P/E Ratio for PHAS stock: -0.357
Will PHAS's stock price go up? Is there an accurate PHAS stock forecast available?
TipRanks.com reports that Phasebio Pharmaceuticals currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $9.50. The target pricing ranges from a high PHAS forecast of $18.00 down to a low forecast of $1.00. Phasebio Pharmaceuticals (PHAS)’s last closing stock price was $0.257 which would put the average price target at 3596.50% upside.
In addition, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on PHAS stock.
Other analysts covering PHAS include:
- Andrew Fein of H.C. Wainwright issued a Buy rating with the price target of $ 18 on 1 month ago
If you are wondering if PHAS is a good stock to buy, here are 3rd party ratings for PHAS stock:
- TipRanks.com: Hold
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 31% (77 out of 251)
What is the sentiment on the street regarding Phasebio Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for PHAS stock: n/a
- Blogger Consensus for PHAS stock: n/a
- Media Buzz for PHAS stock: n/a
- Insider Signal for PHAS stock: n/a
- Investor Sentiment for PHAS stock: Very Negative
- Hedge Fund signal for PHAS stock: Neutral
The stock market is extremely volatile, and you need to do your own research on PHAS stock including scouring the social networks like PHAS StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for PHAS stock chart >>
Summary: Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States.
- Recent AQST Stock Price: $1.16
- Yearly Gain for AQST stock: -74.83%
- Market Cap for AQST stock: $60.82M
- P/E Ratio for AQST stock: -0.645
Will AQST's stock price go up? Is there an accurate AQST stock forecast available?
TipRanks.com reports that Aquestive Therapeutics currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $6.50. The target pricing ranges from a high AQST forecast of $10.00 down to a low forecast of $4.00. Aquestive Therapeutics (AQST)’s last closing stock price was $1.16 which would put the average price target at 460.34% upside.
In addition, Barchart.com has a Weak sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on AQST stock.
Other analysts covering AQST include:
- Liana Moussatos of Wedbush issued a Buy rating with the price target of $ 4 on 23 hours ago
- Ram Selvaraju of H.C. Wainwright issued a Buy rating with the price target of $ 5 on 23 hours ago
- James Molloy of Alliance Global Partners issued a Buy rating with the price target of $ 10 on 4 weeks ago
- Thomas Flaten of Lake Street issued a Buy rating with the price target of $ 7 on 4 months ago
If you are wondering if AQST is a good stock to buy, here are 3rd party ratings for AQST stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 31% (77 out of 251)
What is the sentiment on the street regarding Aquestive Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for AQST stock: Very Bullish
- Blogger Consensus for AQST stock: Bullish
- Media Buzz for AQST stock: Very High
- Insider Signal for AQST stock: n/a
- Investor Sentiment for AQST stock: Negative
- Hedge Fund signal for AQST stock: Neutral
The stock market is extremely volatile, and you need to do your own research on AQST stock including scouring the social networks like AQST StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AQST stock chart >>
Summary: X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States.
- Recent XFOR Stock Price: $1.45
- Yearly Gain for XFOR stock: -76.89%
- Market Cap for XFOR stock: $85.81M
- P/E Ratio for XFOR stock: -0.377
Will XFOR's stock price go up? Is there an accurate XFOR stock forecast available?
TipRanks.com reports that X4 Pharmaceuticals currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $5.50. The target pricing ranges from a high XFOR forecast of $7.00 down to a low forecast of $3.50. X4 Pharmaceuticals (XFOR)’s last closing stock price was $1.45 which would put the average price target at 279.31% upside.
In addition, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on XFOR stock.
Other analysts covering XFOR include:
- Leah R. Cann of Brookline Capital Markets issued a Buy rating with the price target of $ 6.5 on 1 day ago
- Mayank Mamtani of B.Riley Financial issued a Buy rating with the price target of $ 7 on 1 day ago
- Stephen Willey of Stifel Nicolaus issued a Buy rating with the price target of $ 5 on 2 months ago
If you are wondering if XFOR is a good stock to buy, here are 3rd party ratings for XFOR stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 31% (77 out of 251)
What is the sentiment on the street regarding X4 Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for XFOR stock: Very Bullish
- Blogger Consensus for XFOR stock: Bullish
- Media Buzz for XFOR stock: Very High
- Insider Signal for XFOR stock: n/a
- Investor Sentiment for XFOR stock: Very Negative
- Hedge Fund signal for XFOR stock: Neutral
The stock market is extremely volatile, and you need to do your own research on XFOR stock including scouring the social networks like XFOR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for XFOR stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================